You're more than your latest funding, tell our customers your company's story. February 7, 2023 10:51 PM UTC. At the core of this is the ability to deliver DNA better and faster to researchers working on these global challenges. He completed his PhD at the University of Cambridge. Investing in private companies may be considered highly speculative and involves a high degree of risk, including the risk of substantial loss of investment. Ut enim ad minim veniam, aliquip ex ea commodo consequat. Learn more. Before joining Evonetix, Matthew was Head of Technology for the Global Medtech Division of Cambridge Consultants. Prof Klenerman co-developed next-generation DNA sequencing methods that were subsequently commercialised by Solexa (now Illumina), which he also co-founded. We are a Cambridge-based company developing a radically different approach to gene synthesis. site you are consenting to these choices. The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes. She then moved to leadership roles of global multidisciplinary projects to support product development and introduction of new products. As well as leading on financial and related matters, Malcolm was the lead business partner to the sales and marketing, operations, and R&D functions. cale and speed, accelerating scientists' ability to use synthetic biology on a scale not currently possible. Sources. Professor Sir David Klenerman is Professor of Biophysical Chemistry at the University of Cambridge, where he also earned his PhD. Oversubscribed round led by Foresite Capital. Our high calibre team brings together expertise from across the scientific and engineering disciplines. Evonetix brings together the talents of an astonishing group of scientists and engineers, across biology, physics, electronics, chemistry, software and mechanics; all with the same mission, to unlock the capabilities of semiconductor technology for the world of synthetic biology. KioBaser is building what it dubs "Nespresso machine of DNA synthesis". Professor Andrew Briggs is Professor of Nanomaterials at the University of Oxford, where his research focuses on materials and techniques for quantum information technologies and investigating vibrational states of nanotubes and charge transport through single molecules in graphene nanogaps. Dont let your products get skipped. You can find more about their employees through LinkedIn or their website using Zyme Communications The platform aims to deliver less expensive, higher quality, reduced turn-around-time oligonucleotide synthesis solutions. mod tempor incididunt ut labore et dolore magna aliqua. Jason Pontin is a Partner at DCVC, where his belief that emerging technologies and new scientific insights can solve urgent challenges and expand human possibilities inspires his investments in Deep Tech and life sciences companies. Get the full list, To view Evonetixs complete patent history, request access, Youre viewing 5 of 7 executive team members. At TED 2013, he delivered a Talk, Can technology solve our big problems? which has been seen 1.6 million times. She then moved to leadership roles of global multidisciplinary projects to support product development and introduction of new products. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. Get the full list, Youre viewing 5 of 11 investors. Hermann holds an MA in Physics from Vienna University and a PhD in Physics from the University of Cambridge. CAMBRIDGE, England, February 07, 2023--(BUSINESS WIRE)--EVONETIX LTD (Evonetix), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced it has completed a USD $24 million financing round, extending its total series B funding to over USD $54 million (circa GB 44 million). Colin brings over 20 years experience in commercial and business development roles. Stock Market | FinancialContent Business Page Evonetix Stock Price, Funding, Valuation, Revenue & Financial Statements Farfetch Stock: Bull vs. Bear | Nasdaq Helixworks Technologies is a biotechnology company specializing in DNA synthesis. He has delivered commercial success in numerous leadership positions, including Vice President and General Manager and Vice President of Sales at Thermo Fisher Scientific, Vice President and Head of European Sales at Life Technologies and National Sales Manager at Qiagen. We are a new spin-out company that is currently incubating in the centre of the world-renowned Cambridge cluster of high-tech and life science organisations. As a collegial partnership with diverse areas of expertise, they seek to team with and help accelerate the growth of visionary companies breaking barriers and innovating in new markets, especially those creating or leveraging technological advancements in Cloud, Data, Artificial Intelligence, Life Sciences & Health, Mobility, Automation & Robotics, Financial Technology, Security, Blockchain, and Mixed Reality. By continuing to use this site you are consenting to these choices. Michael Daniels joined Evonetix in March 2021 and brings over 20 years experience of marketing, product management and business development across the biotechnology sector. We are seeking to develop and commercialise a new approach to the synthesis of DNA to facilitate the fast-emerging and exciting field of synthetic biology. Cambridge CB1 3LH, Copyright 2023 EvonetixView our Privacy PolicyDesigned & Developed by Identity Creative. We are a new spin-out company that is currently incubating in the centre of the world-renowned Cambridge cluster of high-tech and life science organisations. In addition to this, the company will use the investment to develop its no-code platform that will help manufacturers bridge the existing skills gap and digitise daily operations in such a way that it closes the data loop and brings in the use of AI in factories. Evonetix is a Cambridge-based company developing a radically different approach to gene synthesis. This technology mimics the way nature produces genetic code and enables enhanced performance while minimizing the use of harsh chemicals. Researchers are invited to apply to receive DNA that has been synthesised using Evonetixs platform. Dr. Vishal Gulati is one of the Europes leading digital healthcare investors. Foresite Capitalis an investment firm that aims to transform healthcare by funding visionaries with the courage, data-driven insights and experience to lead the next wave of healthcare companies. site you are consenting to these choices. Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data. The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network. Previously, Dan worked as a Oversubscribed round led by Foresite Capital Funding will enable development of DNA Be first to hear about developments in our technology platform and get access to early release and evaluation opportunities. Get instant access to B2B contact data across the web, We use cookies to improve your browsing experience. Company profile page for Evonetix Ltd including stock price, company news, press releases, executives, board members, and contact information Get the full list, Youre viewing 5 of 10 board members. We use cookies to optimise our website and our service. Evonetix - Overview, News & Competitors | ZoomInfo.com Investment opportunities posted on this website are "private placements" of securities that are not publicly traded, are subject to holding period requirements, and are intended for investors who do not need a liquid investment. Funding will enable development of DNA synthesis chip technology to commercial scale. Bloomberg Daybreak Middle East. He was previously Chief Operations Officer at GreenPeak technologies B.V. (Qorvo Inc.) responsible for the mass production of Zigbee and Bluetooth devices servicing the TV/Set-top-box and IoT markets. He still writes, mostly for WIRED. His investments include Napo Pharmaceuticals, Glenmark, Renovo, Phagenesis. Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems. Matthew Hayes is the Chief Technology Officer of Evonetix, and was a founder member of the team that created the company in 2015. You can read more about your cookie choices at our privacy policyhere. A major contributor to the global technology and growth agendas . Investors of Evonetix include Cambridge Consultants, Morningside Ventures, Molten Ventures, DCVC, Civilization Ventures and 7 more. Evonetix is ready to meet these challenges and open the door to the exciting next phase of our development., To apply to be included in the early access program, please visit: www.evonetix.com/access, View source version on businesswire.com: https://www.businesswire.com/news/home/20220816005493/en/, Lorna Cuddon Trevor Joined Evonetix as COO in January 2023 with over 23 years experience in the semiconductor industry. Evonetix : Quotes, Address, Contact - News-Medical.net Jim assembles the people, ideas and money needed to launch products that save lives and improve healthcare. Jason was raised in Berkeley and on a farm on the North Coast of California, where his family raised game birds for restaurants in the Bay Area. The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user. The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution. At MIT, he founded MIT Solve, the Institutes open innovation platform, which deploys capital and other resources toward solutions to grand challenges; chaired the MIT Enterprise Forum, the Institutes global entrepreneurial community; and was senior advisor to MITs 16th President, Susan Hockfield. The no-code platform aligns human and machine reference data for context specificity, closing the loop intelligently between human activity and assets, for maximum machine learning insight and adaptation. ", Paul Beastall, Chair of the Board of Directors at Evonetix, said: "Were delighted to have secured additional funding from our existing investors in this oversubscribed round, testament not only to the promise of our novel approach to gene synthesis, but also the unrivalled expertise of our interdisciplinary team. He is a Fellow of the Institute of Physics and of the Royal Academy of Engineering, and an Honorary Fellow of Kings College, Cambridge. In 40 year career as an entrepreneur and venture capitalist, Hermann has helped start a number of technology companies, including Acorn Computers and its spin-out ARM, as well as Cambridge Silicon Radio and next-generation DNA sequencing technology company Solexa, which became the market leader and was later acquired by Illumina. Monitor Evonetix job trends. The companys vision is to be the operating system for frontline execution, with insight and best practices shared within and across companies, raising standards and improving workforce productivity across supply chains. Colin McCracken, Chief Executive Officer at Evonetix, commented: "This substantial investment round demonstrates continued confidence in the progress of our technical development and its potential to revolutionise the accessibility of gene synthesis. Let's dig . lorna.cuddon@zymecommunications.com, https://www.businesswire.com/news/home/20220816005493/en/. Evonetix has 10 investors. To find emails, direct dials, and more for prospects across the web. Before that, Trevor held roles as EDA Partner Manager at ARM Holdings, Director of Operations for Samsung Electronics and Director of Programme Management at CSR. Evonetixs proprietary synthesis process utilises a novel silicon chip, to control the synthesis of DNA at many thousands of independent thermally controlled reaction sites, or pixels, and their assembly into highly accurate long DNA on the chip surface through the companys patented Binary Assembly process. Malcolm is responsible for a broad portfolio of financial, HR and other matters. The Company will then look to scale up the parallel synthesis capacity of its semiconductor chips as it works toward future full commercialisation of its technology. Java is a programming language and computing platform. Operator of a biotechnology company intended to synthesize DNA at higher accuracy and scale. Raquel Sanches-Kuiper was appointed Director of Biology of Evonetix in February 2017. The group is managed by investment professionals who are entrepreneurial, have deep industry knowledge and are effective in the local environment in which they operate. Evonetix develops a desktop, short-latency solution to synthesize DNA to facilitate the field of synthetic biology, with applications across industries including healthcare, pharma, biotech, food and agriculture, and data storage. Polyfill as-a-service detects and returns a JavaScript bundle of polyfills based on the cu PHP: Hypertext Preprocessor is a server-side scripting language designed for Web developme Hypertext Markup Language (HTML) is the standard markup language for documents designed to Are you looking for the decision-makers at Evonetix? Matt Hill is the VP of Research and Development at Evonetix, with overall responsibility for the 100-strong team of technologists; spanning engineering, digital and cloud, and science. At the core of this is the ability to deliver DNA better and faster to researchers working on these global challenges. Before You Buy Charles Schwab: Here's a Finance Stock I'd Buy First About Us. Trevor has a BSc in Computer Programming and Chemistry from Anglia Ruskin University. The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution. Matt Hayes, Founder and Chief Technology Officer at Evonetix, said: We have been working on optimising the different elements of our technology ready to share DNA with researchers. EVONETIX LTD (Evonetix), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced the opening of its early access program for semiconductor synthesised DNA. more about the key technologies and tools used by Evonetix and how they Also, check out the jobs and hiring category at Evonetix mentioned earlier on this page to identify Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you. Evonetix is in a very exciting phase, having recently opened our early access program. Request an Annual Quote. Valuation. Copyright 2023 CB Information Services, Inc. All rights reserved. 6sense Chrome Extension. 3 Reasons I'm Bullish on MGM Resorts Stock | The Motley Fool National Stock Exchange of India Limited Exchange Plaza, Plot No. Evonetix General Information. Cambridge Consultants has since grown from revenues of 17M in 2005 to revenues of 120M in 2021, with offices in the US, Singapore and Japan in addition to its headquarters in Cambridge, United Kingdom. Jason was CEO and editor in chief of MIT Technology Review and editor of Red Herring magazine, the bible of the dot.com boom. Evonetix is included in 4 Expert Collections, including Agriculture Technology (Agtech). We use cookies to optimise our website and our service. Paul Beastall is the Head of Strategy and member of the senior leadership team at Cambridge Consultants. Please enter a valid business email id. The company aims to create a benchtop instrument that . Copyright 2023 CB Information Services, Inc. All rights reserved. Also, Molten Ventures joins Zaptics board of directors as part of the investment. He was educated in the United Kingdom at Keble College, Oxford University, where he was awarded a B.A. He is always looking for visionaries: men and women with insights into therapeutics, devices, diagnostics or services that could, with the right support, change the world. Prior to that, Raquel was a post-doctoral researcher in the Department of Chemical Engineering and Biotechnology, University of Cambridge, in the area of cancer gene therapy. The Company has raised $30 million USD (23 million GBP) in this round, which was led by new investor Foresite Capital. His previous roles include Director level positions in Marketing and Product Management at Thermo Fisher Scientific and Arcis Biotechnology, leadership of the Cell and Molecular Research Tools business segment at GE Healthcare and head of Marketing & Business Development at Promega UK. Combined with the Companys patented chemistry, this approach enables the accurate synthesis of thousands of sequences on a single chip to meet the demand for complex libraries and assembly of long DNA, addressing the DNA supply bottleneck in the field of synthetic biology. ", Nelly Markova, Principal, Molten Ventures said: "Molten has been a big supporter of Evonetix from the early days. This fundraise was led by existing investor Foresite Capital, with Molten Ventures, Morningside, DCVC, Cambridge Consultants, Civilization Ventures and Providence also participating in the round. He holds a PhD and MEng in Electronic Engineering, both from Loughborough University. He works across a broad range of sectors from telecommunications to consumer products, focusing on the impact of digital platforms to enable new business models. In a highly competitive market, manufacturers need to enable their workforce to flex across new equipment, processes, and products, with a heavy focus on the alignment of people and data. Prior to that, Raquel was a post-doctoral researcher in the Department of Chemical Engineering and Biotechnology, University of Cambridge, in the area of cancer gene therapy. Investors - Evonetix Evonetix Ltd | LinkedIn By combining DNA polymer synthesis technology, electronic nano-switches and semiconductor fabrication technologies, Iridia is developing a highly-parallel format to enable an array of nanomodules with the potential to store data at exceptionally high density. His interests include understanding the influence of new technologies and how society views their potential impact on human flourishing. Evonetix Closes $24 Million USD (20 Million) Financing CAMBRIDGE, England--(BUSINESS WIRE)--EVONETIX LTD ('Evonetix'), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced it has completed a USD $24 million financing round, extending its total series B funding to over USD $54 million (circa GB 44 million). Evonetix Closes $24 Million USD (20 Million) Financing. Install and uncover Evonetixs employee details in less than 30 secs. Use Slintel to connect with top decision-makers at Evonetix Ltd. He was the first investor in DCVC-backed Totus Medicines, where he is a founding board member, and in Menten.AI. For more information about Evonetix, please visit: www.evonetix.com, View source version on businesswire.com: https://www.businesswire.com/news/home/20230207005697/en/, Lorna CuddonZyme CommunicationsTel: +44(0)7811996942Email: lorna.cuddon@zymecommunications.com, https://www.businesswire.com/news/home/20230207005697/en/, Sony shares tumble on weaker-than-expected annual outlook, 'Waste of time': Community college transfers derail students, Asia Stocks Rise, Treasuries Dip in Cautious Trade: Markets Wrap, Poll: Americans fault news media for dividing country, France Braces for Renewed Anti-Macron Protests on Labor Day. A live simulcast of Bloomberg Television. 9a Coldham's Business Park, Norman Way. The show will focus on global macro issues with a middle eastern context, provide expert analysis of major market moving stories and speak with the biggest newsmakers in the region. The investment round was led by London VC Molten Ventures that recently backed Evonetix and Hadean , with participation from existing investors. Data Collective (DCVC) is a venture capital fund that backs entrepreneurs applying deep tech to transform giant industries. Civilization Ventures leverages an extensive network of world-class scientists and clinicians (including half a dozen MDs and PhDs), as well as accomplished founders and CEOs from our portfolio companies, to gain access to and understand the leading innovations in our space. 1. It is claimed to help users save over 10% in Overall Equipment Effectiveness (OEE) improvement and reduce downtime by up to 20%. Researchers are invited to apply to receive DNA that has been synthesised using Evonetixs platform. To ensure the most secure and best overall experience on our website we recommend the latest versions of, Internet Explorer is no longer supported. Ulta Beauty (NASDAQ: ULTA), which sells cosmetics, seems to have defied this paradigm. This is a profile preview from the PitchBook Platform. We have designed novelsemiconductor technologycapable of synthesising thousands of independent sequences across the surface of a single chip, re-engineered phosphoramidite chemistryto enable thermal control of the synthesis cycle, developednew ways to assemble DNAinto genes and established novel approaches toenzymatic DNAsynthesis. Evonetix raises $24 million for DNA synthesis - cen.acs.org In 2004, he was appointed a member of the Government Council for Science & Technology. You can find their contact number, email address, and headquarters by All trademarks are the property of Evonetix Ltd. or their respective owners. The streaming video giant is slated to give investors its first-quarter earnings update in . Bed Bath & Beyond stock rises 5.3% premarket - MarketWatch